Moreover, recent analysis using next-generation sequencing has revealed that BCR-ABL1-dependent or-independent mutations exist in patients with poor response to TKIs [106,107], suggesting that neoantigens other than known CML antigens could be targeted by immune checkpoint inhibitor (ICI)-activated CTLs which reside in these CML patients. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.